Skinny Label Patent Infringement: How Hikma v. Amarin Could Reshape Generic Drug Law
The Supreme Court is poised to decide one of the most consequential questions in pharmaceutical patent law: when does a generic drug’s marketing create skinny label patent infringement liability? Continue reading…